Christopher Wommack, MD
Family Medicine · Columbus, GANPI 1962403808
Payments from drug & device makers
Across 381 payments — averaging $14.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$689
- Lilly USA, LLC$570
- AstraZeneca$352
- Astellas Pharma US Inc$349
- Amgen$292
- plus $2K from 24 others
What the payments were for
- Food & beverage$5,46096%
- Education$2004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 127 | $1,402 |
| AbbVie(2 entities) | 45 | $689 |
| Lilly USA, LLC | 44 | $570 |
| AstraZeneca | 20 | $352 |
| Astellas Pharma US Inc | 10 | $349 |
| Amgen(2 entities) | 18 | $292 |
| Novartis | 18 | $285 |
| Boehringer Ingelheim | 16 | $266 |
| GSK | 14 | $232 |
| Pfizer | 9 | $159 |
| Medtronic(2 entities) | 4 | $142 |
| Esperion Therapeutics, Inc. | 8 | $113 |
| Abbott | 5 | $110 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $104 |
| Biohaven Pharmaceuticals, Inc. | 6 | $90 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $84 |
| Merck | 5 | $80 |
| Eisai Inc. | 4 | $61 |
| Bayer | 2 | $42 |
| Exact Sciences | 2 | $32 |
| Currax Pharmaceuticals LLC | 2 | $29 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Johnson & Johnson | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Bausch Health US, LLC | 1 | $21 |
| Tolmar, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
How this compares
$5,660 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 62 | $76,335 |
| OzempicSemaglutide | 52 | $68,348 |
| MounjaroTirzepatide | 49 | $60,032 |
| FarxigaDapagliflozin Propanediol | 44 | $53,380 |
| JanuviaSitagliptin Phosphate | 34 | $48,232 |
| EliquisApixaban | 33 | $41,895 |
| XareltoRivaroxaban | 36 | $35,641 |
| Tresiba Flextouch U-100Insulin Degludec | 64 | $32,485 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $18,260 |
| MyrbetriqMirabegron | 28 | $17,524 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $13,700 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $12,466 |
| Emgality PenGalcanezumab-Gnlm | 12 | $8,337 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,103 |
| LivaloPitavastatin Calcium | 18 | $6,961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $266 | $82,94673 claims |
| Novo NordiskOzempic | $1,402 | $68,34852 claims |
| MerckJanuvia, Janumet | $80 | $66,49345 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $352 | $65,84658 claims |
| Lilly USA, LLCMounjaro | $570 | $60,03249 claims |
| PfizerEliquis | $159 | $41,89533 claims |
| Johnson & JohnsonXarelto | $26 | $35,64136 claims |
| Astellas Pharma US IncMyrbetriq | $349 | $17,52428 claims |
| GSKTrelegy Ellipta, Shingrix | $232 | $13,66338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Columbus
- Joseph SurberColumbus$16.6M
- Jeffrey KingsleyColumbus$8.1M
- Bantwal BaligaColumbus$117K
- Megbewe OkorobaColumbus$61K
- Kimberly Brown-GullattColumbus$35K
- Angela RitterGainesville$15.8M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.